Trial · NCT07570017
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT07570017, Phase 1, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Trials, record NCT07570017. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07570017
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- NCT number
- NCT07570017
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 42 participants, estimated
- Lead sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Conditions
- DLBCL
- Interventions
- Rocbrutinib, R-GemOx
- First posted
- 2026-05-06
- Last updated
- 2026-09-10
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | DLTs | At the end of Cycle 1 (the length of cycle 1 is 21 days) | Dose-Limiting Toxicities |
| Primary | MTD | At the end of Cycle 1 (the length of cycle 1 is 21 days) | Maximum Tolerated Dose |
| Primary | Adverse events as assessed by CTCAE v5.0 | From the first administration to 28 days after the last administration | |
| Secondary | ORR | Up to approximately two years | Overall Response Rate |
| Secondary | TTR | Up to approximately two years | Time to Response |
| Secondary | DoR | Up to approximately two years | Duration of Response |
| Secondary | PFS | Up to approximately two years | Progression-free Survival |
| Secondary | OS | Up to approximately two years | Overall Survival |
| Secondary | Cmax | From 1 hour prior to administration to 24 hours post-dose | Maximum Plasma Concentration |
| Secondary | Tmax | From 1 hour prior to administration to 24 hours post-dose | Time to Maximum Plasma Concentration |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07570017
GET https://conductscience.org/api/trials/v1/NCT07570017/registered